ANI Pharma's Bid to Import Key Controlled Drugs
Published Date: 5/4/2026
Notice
Summary
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
Analyzed Economic Effects
4 provisions identified: 2 benefits, 2 costs, 0 mixed.
No Import of Finished Dosage Forms
The notice states that authorization for this import registration will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale. Permit approval will be limited to activities consistent with 21 U.S.C. 952(a)(2).
Comment and Hearing Deadline
Registered bulk manufacturers and applicants may submit electronic comments or objections, or file a written request for a hearing, on ANI Pharmaceuticals Inc.'s importer application by June 3, 2026. Comments must be submitted through Regulations.gov or hearing requests sent to the DEA addresses listed in the notice.
Levorphanol Import Authorization Sought
ANI Pharmaceuticals applied to be registered to import Levorphanol (controlled substance code 9220, Schedule II) for distribution to customers. If the registration is granted, this import authorization would cover Levorphanol distribution as described in the application.
Tapentadol Import Limited to Research
ANI applied to import Tapentadol (controlled substance code 9780, Schedule II) only in small quantities for internal research and reference standards purposes. The application states no other activities for this drug code are authorized for this registration.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-13145 — Importer of Controlled Substances Application: Almac Clinical Services Incorp. (ACSI)
Almac Clinical Services Incorp. (ACSI) wants to become an official importer of certain controlled substances, including psilocybin and oxycodone. This affects drug manufacturers and others in the industry who can comment or request a hearing by July 30, 2026. No direct costs are mentioned, but the decision could impact how these substances enter the U.S. market.
2026-13144 — Importer of Controlled Substances Application: Catalent Pharma Solutions, LLC
Catalent Pharma Solutions wants to become an official importer of some powerful controlled substances like LSD and psilocybin. People who make or use these drugs can share their thoughts or ask for a hearing by July 30, 2026. This move could impact companies involved in these substances and the government’s control over them.
2026-12654 — Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I
Starting July 24, 2026, O-desmethyltramadol (also called O-DSMT) will be temporarily placed in Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even just possesses it, bringing strict rules and penalties. The move aims to keep people safe while the government studies the drug more closely.
2026-12653 — Schedules of Controlled Substances: Placement of Bromazolam in Schedule I; Correction
The DEA fixed a typo in the official chemical name of bromazolam, a drug they put in the strictest Schedule I category starting March 16, 2026. This correction makes the rules clear for everyone involved, especially law enforcement and drug handlers. No new fees or deadlines, just a clean-up to keep things accurate and official.
Previous / Next Documents
Previous: 2026-08586 — Bulk Manufacturer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to make a big batch of a strong medicine called Levorphanol, which is a controlled substance. This affects people in the drug manufacturing and regulation world, and the public can share their thoughts or ask for a hearing by July 6, 2026. If approved, ANI will help develop new medicines, but no other activities with this drug are allowed under this registration.
Next: 2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.